S troke-survivors are at particular risk of cognitive decline. Three month dementia prevalence is ≥30%, and even minor stroke events have cognitive sequel.
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Collation and synthesis of the evidence around cognitive screening tools will help guide policy and practice and highlight knowledge gaps. We sought to perform systematic review and meta-analysis, describing accuracy of screening tools for assessing dementia and multidomain cognitive impairment in stroke-survivors.
Methods
We used systematic literature review and meta-analysis techniques specific to test accuracy 13 and followed best practice in reporting. 14 
Aims
Coprimary aims were to describe the following:
1. Accuracy of cognitive screening tests for clinical diagnosis of multidomain, cognitive impairment/dementia in stroke-survivors. 2. Accuracy of brief (<5 minutes completion time), cognitive screening tests against more detailed neuropsychological assessments.
If data allowed, secondary objectives were to compare differing cutpoint scores used to define a threshold of test positivity and to compare the effects of heterogeneity with specific reference to test context and diagnostic reference standard.
Index Test
Index tests of interest were any direct-to-patient, cognitive screening tests. We included any screening test where the authors described it as such. We excluded informant-based assessments and tests that require testing equipment considered nonstandard for a stroke service. We recognize that language and visuospatial function are important components of cognition, but did not include assessments of tools designed to exclusively test these domains. We did not include studies that compared screening tools with no reference to diagnostic gold standard.
Target Condition and Reference Standard
Our target condition of interest was all-cause (undifferentiated) multidomain cognitive impairment post stroke. This rubric recognizes that a diagnosis of important poststroke cognitive problems can be made without necessarily assigning a dementia label or specifying a pathological subtype.
As reference standard, we included clinical diagnosis of dementia made using any recognized classification system. We also included multidomain, cognitive problems as detailed on a neuropsychological assessment, provided the test battery was comprehensive and the results were interpreted to give a diagnostic formulation. We did not include single domain cognitive impairment or cognitive impairment no dementia because of inconsistency in operationalization of these syndromes. 15 We prespecified subgroup analyses comparing dementia diagnosis and neuropsychological battery-based diagnosis.
For assessment of brief tests, we accepted results from a more detailed multidomain, screening assessment as reference standard, for example, comparison of Hodgkinson's abbreviated mental test against Folstein's Mini Mental State Examination (MMSE).
Participants and Setting
Our focus was stroke-survivors. Where study population was a mix of stroke survivors and other patients, we included if proportion of stroke-survivors was >75%. We made no distinction between stroke subtypes, but excluded studies of traumatic intracerebral hemorrhage and subarachnoid hemorrhage. We did not include case studies (defined as having fewer than 10 participants).
We included studies conducted in any clinical setting and at any time post stroke. We operationalized time since stroke as hyperacute (first 7 days); acute (8-14 days); post acute (15 days to 3 months); medium term (3-12 months), and longer term (post 1 year).
Search Strategy
All aspects of searching, data extraction, and study assessment were performed by 2 reviewers (RL, JS) based in different centers and blinded to each others' results. On review of paired data, disagreement was resolved by group discussion.
We developed a sensitive search strategy in collaboration with an Information Scientist (CF) and with assistance from the Cochrane Dementia and Cognitive Improvement Group. Search terms were developed using a concepts-based approach, using Medical Subject Heading terms and other controlled vocabulary. Concepts of interest were stroke, dementia, and cognitive assessment. Our cognitive assessment concept included terms relating to cognitive tests used in stroke, based on previous survey data. 9, 10 We searched multiple, international, cross-disciplinary electronic databases from inception to January 2014. (Full search strategy is detailed in the online-only Data Supplement I-II.) We checked reference lists of relevant studies and reviews for further titles, repeating the process until no new titles were found.
We screened all titles generated by initial searches for relevance, and corresponding abstracts were assessed and potentially eligible studies reviewed as full manuscripts against inclusion criteria. As a check of internal validity, a random selection of 2000 titles from the original search was reassessed by a third author (TQ). We tested external validity of our search by sharing lists of included articles with independent researchers (Acknowledgments). One author (TQ) identified exemplar articles relevant to the review question (online-only Data Supplement II), and we assessed whether these titles were detected by search strategy.
Data Extraction and Management
We extracted data to a study-specific proforma piloted against 2 articles (available from contact author).
For screening tests that give an ordinal summary score, various cutpoints can be used to define test positive cases. Where data were given for several thresholds, we extracted separate data for each. Where a study may have included useable data, but these were not presented in the published article, we contacted the authors directly. If the same data set was presented in >1 publication, we included the primary article.
Quality Assessment
We assessed quality of study reporting using the dementia-specific extension to the Standards for Reporting of Diagnostic Accuracy checklist. 16 We assessed methodological quality using the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2). 17 We have previously developed QUADAS-2 anchoring statements specific to cognitive assessment.
18

Statistical Analysis
We assessed accuracy of screening tests against a dichotomous variable cognitive impairment/no cognitive impairment. We created standard 2-by-2 data tables describing binary test results cross-classified with binary reference standard. We did not include case-control studies in pooled analyses. We used accepted cut-offs for multidomain impairment/dementia published in the literature: Addenbrooke's Cognitive Examination-Revised <88, Rotterdam-CAMCOG<33, MMSE<27, and <25. For Montreal Cognitive Assessment (MoCA), a cut-off of <26 was used together with the lower cut-off of <22 because the former was developed to detect single-domain impairment.
Where data allowed, we calculated sensitivity, specificity, and corresponding 95% confidence intervals (95% CI) and created test accuracy forest plots (RevMan 5.1, Cochrane Collaboration). We pooled test accuracy data using the bivariate approach (Statistical Analysis Software v9.1; SAS Institute Inc, USA). We used a bespoke macro developed with assistance of a statistical team with an interest in test accuracy. 19 Summary metrics of interest were sensitivity/specificity and positive/negative likelihood ratios and clinical utility index. 20 We created summary curves in received operating characteristic space with corresponding 95% prediction intervals.
We assessed potential heterogeneity through visual inspection of forest plots. We prespecified 2 factors that may contribute to heterogeneity, timing of assessment and reference standard. We dichotomized studies into acute (classified as hyperacute or acute) or nonacute and described reference standard as clinical (clinical diagnosis of dementia) and by guest on April 13, 2017 http://stroke.ahajournals.org/ Downloaded from neuropsychological battery (multidomain cognitive impairment). We assessed effect by plotting summary received operating characteristic curves by covariate. Taking timing of assessment as example, we calculated sensitivity/specificity restricted to the single cognitive assessment with greatest number of studies. We described a relative sensitivity/specificity comparing acute and nonacute studies, where a result of unity suggests no difference in that diagnostic property between settings. We did not quantify publication bias because there is no assessment applicable to test accuracy.
Where articles fulfilled inclusion criteria but did not have data suitable for this method of analysis, we offer a tabulated/narrative description.
Results
From 19 182 titles, we reviewed 241 full articles of which 35 (34 data sets) were suitable for inclusion. Scope of included literature was international, with articles from 16 different countries.
We detailed the study selection process in a Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram ( Figure 1) .
Our validation check suggested the initial search was appropriate because all prespecified articles were found on first search. 
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Accuracy of Screening Tools for Diagnosis of Cognitive Impairment
In total n=32 articles (n=3562 participants) were eligible. We tabulated summary descriptors for studies using clinical diagnosis reference standard (n=11 articles) 22, 24, 34, [37] [38] [39] 43, 47, 49, 51, 52 and those using detailed neuropsychological assessment (n=21 ; Tables 1-2) . 21, 23, [25] [26] [27] [28] [29] [30] [31] [32] [33] 35, 36, [40] [41] [42] [44] [45] [46] 48, 50 There was considerable heterogeneity in study population: setting and test strategy. Twenty-three different tests were described, commonest MMSE (n=16 articles) and MoCA (n=8; Tables 1-2; online-only Data Supplement III).
Screening tests gave a spread of test accuracy, sensitivity range 14% to 100%, and specificity range 0% to 100% with trade-off between sensitivity and specificity. Where authors compared >1 test in the same population, the comparator was usually MMSE, and for most articles, MMSE was more specific and less sensitive than other tests. Both the Executive Function Performance Test and the Repeatable Battery for Assessment of Neuropsychological Status showed strong correlations with scores on neuropsychological batteries, but data were not suitable for pooled analysis.
25-28
Quality and Reporting
One article was graded low risk for all QUADAS2 domains. 21 Common issues of concern were use of case-control methodology (n=7 articles) and potential lack of blinding (n=12; Figure 2 ; online-only Data Supplement IV). Five articles attempted to include patients with moderate to severe aphasia. [21] [22] [23] [24] [25] Standards for Reporting of Diagnostic Accuracy assessment suggested consistent areas of poor reporting, particularly around the handling of missing data (n=22 articles) and descriptions of training and expertise of assessors (n=25 articles; online-only Data Supplement V)
Meta-Analyses
We were able to pool test accuracy data for 4 tests: Addenbrooke's Cognitive Examination-Revised (threshold score ≤88); MMSE (thresholds ≤24 and ≤26), MoCA (thresholds <26 and <22), and Rotterdam-CAMCOG (threshold <33). No test had sensitivity and specificity that were significantly different from others. MoCA at traditional threshold was sensitive at cost of specificity; specificity improved if thresholds were adjusted (Table 3; Figure 3 ; online-only Data Supplement VI)
Heterogeneity
We assessed effect of timing and reference standard using MMSE data. Comparing 6 acute studies 20, 21, 31, 37, 38, 43 and 6 nonacute studies 22, 30, 34, 39, 46, 50 ; gave a relative sensitivity, 0.73 (95% CI, 0.58-0.93) and relative specificity, 1.12 (95% CI, 1.01-1.25). These data suggest that accuracy varies with assessment timing and context, with acute testing yielding higher sensitivity and lower specificity. From analysis of paired summary received operating characteristic curves, the overall accuracy was better for those studies where assessment was performed within the acute period (online-only Data Supplement VII). Comparing clinical dementia reference standard 21, 24, 40, 47, 52 against neuropsychological battery 23, 32, 33, 36, 39, 41, 45, 46 suggested no difference in test properties dependent on the reference standard used, with relative sensitivity of 0.86 (95% CI, 0.67-1.11) and relative specificity of 1.05 (95% CI, 0.95-1.16). 
Accuracy of Brief Tools
We found 3 suitable articles (n=294 participants; online-only Data Supplement VIII). [53] [54] [55] Two articles were graded high risk of bias and applicability concerns because of case-control methodology and patient inclusion.
53,55
Discussion
Previous systematic reviews of cognitive test accuracy have focused on older adults with narrative results only. Our aim was to provide a stroke-specific, literature synthesis to allow evidence-based recommendations on cognitive testing. We were partially successful in this aim. Although there is an extensive, cross-disciplinary literature describing cognitive testing in stroke, number of articles using the classical test accuracy paradigm of index test versus reference (gold) standard was limited. Eligible articles were characterized by substantial heterogeneity and risk of bias, and the potential to describe summary analyses at individual test level was limited.
Accepting these caveats, we can still offer conclusions from our pooled analysis. There was no clearly superior cognitive screening test. Given the relative consistency in accuracy, choice of test strategy should be informed by other factors, 
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such as purpose of testing, feasibility; acceptability, and opportunity cost. Recent guidance and practice has tended to favor novel tests compared with the traditionally popular MMSE. 6, 7, 56 Although there may be good reasons to favor other tests, our data do not suggest that MMSE is inferior for the diagnosis of multidomain impairment, albeit MMSE may lack sensitivity for single domain impairment. 15, 46, 56 There was a trend toward better clinical utility for Rotterdam-CAMCOG, but the small number of studies and corresponding wide confidence intervals precludes definitive recommendation.
Preferred test properties will depend on test purpose, particularly the level of cognitive impairment to be detected. It could be argued that for initial screening, sensitivity is preferred compared with specificity. In this case, MoCA and Addenbrooke's Cognitive Examination-Revised may be preferred. The high false-positive rate for multidomain impairment obtained using MoCA <26 is to be expected because this threshold was chosen for detection of single domain impairment/mild cognitive impairment. 15, 46 Our findings suggest that an adjusted cut-off <22 has improved overall test properties for multidomain impairment in stroke as suggested previously. 15, 46 We were pragmatic in our choice of index test and reference standard. Our screening test rubric included relatively short assessments (MoCA) through to fairly lengthy batteries (Repeatable Battery for Assessment of Neuropsychological Status). We did not find significant improvements in sensitivity/specificity comparing shorter and longer screens (MoCA and Addenbrooke's Cognitive Examination-Revised). This may suggest that increasing the length of test batteries does not necessarily improve the test accuracy.
There is no universally accepted gold standard for dementia. Rather than restricting to a particular pathological subtype, our focus was all cause dementia post stroke. We think this approach is in keeping with current clinical practice, where initial screening highlights potential cognitive issues that can subsequently be characterized with more detailed assessments. Literature describing screening tests for diagnosis of specific dementia subtypes was limited, and we were only able to describe test accuracy for all cause (undifferentiated) dementia. A priori, we decided to include multidomain impairment based on neuropsychological assessment in our reference standard, and this approach maximized potential for pooled analysis and recognizes that clinical diagnosis in certain stroke situations is not always feasible or appropriate. We used multidomain rather than single domain impairment because this is closest to current operational classifications of dementia. We did not specify content of the neuropsychological assessment and recognize the substantial heterogeneity in batteries used. 15 There were many potential sources of heterogeneity (sample size, case-control methodology, investigator training); indeed a degree of heterogeneity is expected in test accuracy metaanalyses. We were not able to assess all potentially contributory factors across the modest number of included studies and accept that this limits our findings. We chose to focus on reference standard and timing of assessment as the most important possible sources of heterogeneity. We found that test properties varied with timing and seemed to favor earlier assessment, albeit our rubric of acute assessment included studies from first hours ≤14 days post ictus. Comparative analysis of test properties require careful interpretation; a conservative interpretation would be that a test suitable for longer-term poststroke assessment may not be suitable for early assessment and that cognitive testing can (and should) be performed in the acute stroke unit. Brief assessment tools are attractive for use in busy stroke settings but only if they have acceptable accuracy. In this regard, the limited number of studies looking at brief assessments is unfortunate. Based on data available, screening using clock drawing test or abbreviated mental test may have a role for initial assessment; but they should not be considered a substitute for subsequent multidomain testing.
Limitations of Included Studies
Our review highlights issues in the design and reporting of cognitive test accuracy studies. There was little reporting of missing or indeterminate data; however, we know that substantial numbers of stroke patients are unable to complete multidomain screening tools. The same concern holds for a reference standard based on extensive neuropsychological testing. Limiting test accuracy data to those able to complete testing will bias results, tending to inflate test accuracy. We would encourage use of the intention to diagnose approach, where the traditional 2×2 test accuracy table is expanded with cells representing those unable to complete index test and reference standard. 57 A related issue is around generalizability of the included subjects. In our quality assessment, we scored several articles as inappropriate exclusion, including the studies that excluded patients with moderate to severe aphasia or inability to consent. We recognize the challenges of cognitive testing in this group, who by definition have at least single domain impairment; however, excluding patients with communication problems or frank confusion from test accuracy research will limit external validity.
Strengths and Limitations of Review
Our review provides a contemporary synthesis of the rapidly evolving field of cognitive screening in stroke. We offer a sensitive search strategy following best practice in conduct and reporting 58 and with multiple embedded internal and external validity checks. The review has limitations; our focused question excluded potentially informative articles, for example where screening tests are compared against each other. 59 We did not assess other important test metrics, such as responsiveness to change or reliability, or other cognitive states, such as (single domain) mild cognitive impairment. These questions would need their own review. We recognize that cognitive assessment in stroke is evolving; 15 (47%) of included articles in our primary review were published since 2010. Novel, stroke cognition assessments are emerging, but no test accuracy data were available at time of review.
Future Research
Our subgroup analysis suggests that test accuracy will vary depending on time since stroke, but could not suggest an optimal time for assessment. Early assessment in the Acute Stroke Unit has practical advantages and could allow for timely intervention; however, few studies assessed patients in the acute period. Given the issues with generalizability and missing data, future studies may wish to describe feasibility and acceptability of testing, as well as classical test accuracy metrics.
Conclusions
All our results must be interpreted with caution as included studies had substantial heterogeneity and potential for bias. However, we can offer some practical advice to clinicians. There is no clearly superior cognitive screening test approach and no evidence that newer or longer screening tests necessarily offer better test accuracy than established screens with shorter administration time. The strategy for cognitive testing in stroke must be informed by the purpose of the test and by other metrics, such as feasibility, acceptability, and opportunity cost. If the purpose of the initial screening is to pick-up all potential cases to allow further assessment, then MoCA may be the preferable test because it offers high sensitivity with shorter administration time than other equally sensitive tests. For MoCA use in stroke, screen positive thresholds may need to be adapted if the aim is to assess for dementia/multidomain impairment, and test accuracy may vary with time since stroke event. Agrell 2000 Forest plot of R-CAMCOG (threshold 25) for dementia / cognitive impairment (n=2 studies)
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